Phaseline

Targets › IAP

IAP: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: the race on IAP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Taiho OncologyASTX660
IAP inhibitor
IAPPhase 1Solid Tumors; Advanced CancerDec 2027

Conditions

Solid Tumors (1) Advanced Cancer (1)

Modalities

small molecule (1)

Companies

Taiho Oncology (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.